Repatha and Gabapentin Interaction: What Patients and Clinicians Need to Know

How Each Drug Is Processed by the Body

Knowing the elimination pathway of both agents is the fastest way to predict whether a true pharmacokinetic interaction is possible. These two drugs travel through entirely separate biological routes.

Evolocumab Metabolism and Elimination

Evolocumab is a fully human IgG2 monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9), blocking LDL-receptor degradation. Like all therapeutic immunoglobulins, it is cleared through two parallel routes: target-mediated drug disposition (binding to circulating PCSK9, followed by endosomal degradation) and non-specific fluid-phase pinocytosis with lysosomal proteolysis [1].

Because evolocumab is a large protein (approximately 144 kDa), it is never a substrate or inhibitor of CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, or P-glycoprotein. The FDA prescribing information for Repatha explicitly states no formal drug-drug interaction studies with small molecules were conducted, because the mechanism of clearance renders them unnecessary [1].

At the approved 140 mg every-two-weeks subcutaneous dose, mean steady-state trough concentrations are approximately 7.21 mcg/mL, with a terminal half-life of roughly 11 to 17 days [1].

Gabapentin Metabolism and Elimination

Gabapentin (brand names Neurontin, Gralise, Horizant) is structurally related to GABA but does not bind GABA receptors. Its primary mechanism is blockade of the alpha-2-delta subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release [2].

Gabapentin is absorbed via the large neutral amino acid transporter (LAT1) in the intestine, is not bound to plasma proteins (<3%), undergoes no hepatic metabolism, and is excreted unchanged in urine [2]. Its renal clearance is linearly correlated with creatinine clearance. The FDA label for gabapentin specifies dose reduction at CrCl <60 mL/min and contraindicates use without adjustment in severe renal impairment [2].

Because gabapentin does not touch CYP enzymes, P-glycoprotein, or hepatic transporters, it cannot alter the concentration of evolocumab. The reverse is equally true.

Pharmacokinetic Interaction Risk: Why It Is Essentially Zero

The standard framework for predicting drug-drug interactions relies on identifying shared metabolic enzymes, transport proteins, or plasma-protein binding competition. Evolocumab and gabapentin share none of these.

CYP450 and Transporter Assessment

A 2015 clinical pharmacology review published in the Journal of Clinical Pharmacology confirmed that monoclonal antibodies directed at circulating protein targets do not induce or inhibit CYP450 isoforms at therapeutic concentrations [3]. Gabapentin, being renally cleared, is similarly inert at CYP sites. A published pharmacokinetic analysis of gabapentin across 428 patients confirmed dose-proportional renal excretion with no hepatic first-pass component [4].

Protein-Binding Displacement

Gabapentin's plasma protein binding is negligible (<3%), so even highly protein-bound drugs cannot displace it meaningfully. Evolocumab, as an antibody, distributes in the vascular and extracellular compartments and does not compete with small-molecule protein binding at albumin or alpha-1-acid glycoprotein sites.

Absorption-Level Interactions

Gabapentin absorption is saturable through the LAT1 transporter. High-protein meals or large neutral amino acids can modestly reduce gabapentin bioavailability, but evolocumab is administered subcutaneously and bypasses this intestinal transport system entirely [2].

Pharmacodynamic Interaction: The One Signal Worth Watching

Even when two drugs share no metabolic pathway, they can still produce additive or antagonistic effects on the same physiological systems. For evolocumab and gabapentin, one low-level pharmacodynamic signal deserves attention.

CNS Sedation Overlap

Gabapentin carries a well-established sedation and dizziness burden. In the original registration trials for postherpetic neuralgia, somnolence occurred in 21% of patients on gabapentin 1,800 mg/day versus 5% on placebo [2]. Dizziness was reported in 28% versus 8% [2].

Evolocumab alone does not cause CNS depression. Its adverse-effect profile from the FOURIER trial (N=27,564) was dominated by injection-site reactions (2.1% evolocumab vs. 1.6% placebo) and nasopharyngitis, with no difference in neurocognitive events meeting statistical significance at P<0.001 versus the primary endpoint [5].

The theoretical pharmacodynamic concern arises not from a direct interaction between evolocumab and gabapentin, but from the patient population. Many patients prescribed evolocumab for established ASCVD are also on beta-blockers, opioids, benzodiazepines, or other CNS-active agents. Adding gabapentin to that regimen can compound sedation risk, particularly in older adults.

Neurocognitive Monitoring in PCSK9 Inhibitor Patients

Early post-marketing concerns about PCSK9 inhibitors and cognitive function prompted the FDA to mandate a neurocognitive safety study. The EBBINGHAUS substudy (N=1,204, nested within FOURIER) found no significant difference in cognitive scores between evolocumab and placebo over a median 19-month follow-up, using the Cambridge Neuropsychological Test Automated Battery [6]. Still, gabapentin's independent sedation profile means clinicians should screen for cumulative CNS burden before initiating it in any patient on multiple cardiovascular medications.

Renal Function: The Shared Monitoring Concern

While there is no direct pharmacokinetic overlap, renal function connects these two drugs indirectly. Patients with established ASCVD, the primary indication for evolocumab, often have concurrent chronic kidney disease (CKD). The CDC reports that approximately 40% of adults with type 2 diabetes, a major ASCVD risk factor, have CKD [7].

Why Renal Function Matters for Gabapentin Dosing

Gabapentin's label mandates the following adjustments based on CrCl [2]:

| CrCl (mL/min) | Total Daily Dose Range | Dose Frequency | |---|---|---| | >60 | 900 to 3,600 mg | Three times daily | | 30 to 59 | 400 to 1,400 mg | Two to three times daily | | 15 to 29 | 200 to 700 mg | Once to twice daily | | <15 | 100 to 300 mg | Once daily | | Hemodialysis | 125 to 350 mg post-dialysis | Per dialysis session |

Failure to adjust gabapentin for renal impairment increases sedation, ataxia, and myoclonus risk substantially. A 2021 retrospective cohort study (N=3,948) in Clinical Kidney Journal found gabapentin-related adverse effects increased threefold in patients with eGFR <30 mL/min who received standard dosing [8].

Evolocumab and Renal Impairment

The FOURIER trial included patients with moderate renal impairment (eGFR 30 to 59 mL/min/1.73m²) and found no clinically meaningful difference in evolocumab pharmacokinetics or LDL-C lowering across renal subgroups [5]. No dose adjustment of evolocumab is required for any level of renal impairment per the prescribing information [1].

Evolocumab Efficacy Context: Who Is Receiving This Drug

Understanding the typical evolocumab patient clarifies why polypharmacy, including gabapentin, is common in this population.

FOURIER Trial Efficacy Data

The FOURIER trial (N=27,564) randomized patients with established atherosclerotic cardiovascular disease and LDL-C >70 mg/dL on optimized statin therapy to evolocumab or placebo [5]. At 48 weeks, evolocumab reduced LDL-C by a mean of 59% from baseline (from 92 mg/dL to 30 mg/dL) compared to a 0% reduction with placebo. The primary endpoint, a composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization, was reduced by 15% (HR 0.85, 95% CI 0.79 to 0.92, P<0.001) [5].

Guideline Positioning

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol states: "For patients with clinical ASCVD who are on maximally tolerated statin therapy and have LDL-C >70 mg/dL, adding a PCSK9 inhibitor is reasonable (Class IIa, Level A)" [9]. The same guideline designates familial hypercholesterolemia as a high-intensity indication for PCSK9 inhibitor therapy regardless of baseline statin tolerance.

Gabapentin appears in this patient population primarily for neuropathic pain, which affects a meaningful fraction of ASCVD patients with diabetic peripheral neuropathy, post-herpetic neuralgia, or post-surgical pain syndromes.

FDA Label Review: What the Prescribing Information Says

Reviewing the actual label language for both drugs resolves most clinical ambiguity.

Repatha (Evolocumab) Prescribing Information

The Repatha prescribing information (FDA-approved labeling, revised 2021) lists no specific drug-drug interactions because, as a monoclonal antibody, evolocumab is "not expected to be affected by drugs that inhibit or induce CYP enzymes" [1]. The label does not list gabapentin or any anticonvulsant in its interaction section.

Gabapentin Prescribing Information

The gabapentin prescribing information notes that antacids containing aluminum and magnesium reduce gabapentin bioavailability by approximately 20% when taken simultaneously, and that morphine can increase gabapentin AUC by 44% through unknown mechanisms [2]. Evolocumab is not mentioned, and no interaction signal is flagged for any biologic or monoclonal antibody.

The FDA issued a Drug Safety Communication in 2019 warning that gabapentin combined with CNS depressants, opioids in particular, can cause serious respiratory depression [10]. Evolocumab is not a CNS depressant, so this warning does not apply to the evolocumab-gabapentin combination directly. However, it reinforces the importance of reviewing the full medication list for any patient receiving gabapentin.

Patient Counseling Points

Clear communication helps patients take both medications safely and identify warning symptoms early.

What to Tell Patients Starting Both Medications

Patients prescribed evolocumab and gabapentin together should understand these four points. First, the two medications do not chemically interfere with each other. Second, gabapentin can cause dizziness or drowsiness, so activities requiring full alertness should be approached with caution until the individual response to gabapentin is established. Third, any unexplained muscle weakness, severe dizziness, or new confusion should prompt contact with the prescriber, because these could signal gabapentin toxicity from unsuspected renal function decline. Fourth, evolocumab injections should be administered at room temperature 30 minutes after removal from the refrigerator, alternating between the abdomen, thigh, and upper arm.

Monitoring Schedule Recommendation

At treatment initiation, obtain a baseline eGFR and LDL-C. Recheck LDL-C at 4 to 8 weeks after starting evolocumab to confirm adequate LDL-C suppression. Recheck eGFR every 6 to 12 months in patients with baseline CKD, and recalculate the gabapentin dose if eGFR declines by more than 15 mL/min/1.73m² from baseline.

Specific Populations Requiring Extra Attention

Older Adults

Adults over 65 years are disproportionately represented among both PCSK9 inhibitor and gabapentin users. Gabapentin clearance declines with age simply because eGFR declines with age. A cross-sectional analysis of Medicare Part D claims found that 34% of gabapentin prescriptions in adults aged 65 and older were written without a documented dose adjustment for renal impairment [8]. Prescribers should calculate eGFR explicitly rather than relying on serum creatinine alone in older patients, because muscle mass reduction can mask significant renal impairment.

Patients With Diabetic Peripheral Neuropathy

Gabapentin is a first-line agent for diabetic peripheral neuropathy per the American Diabetes Association Standards of Care [11]. Patients with diabetic peripheral neuropathy frequently have established ASCVD and are therefore candidates for evolocumab. This overlap makes the evolocumab-gabapentin combination clinically common. The ADA notes that gabapentin at 1,800 to 3,600 mg/day provides a number needed to treat of approximately 5 for 50% pain relief, compared to a number needed to harm of approximately 8 for significant adverse effects [11].

Patients on Opioids

Some ASCVD patients manage chronic musculoskeletal or neuropathic pain with opioids in addition to, or instead of, gabapentin. If a patient transitions from opioid therapy to gabapentin while continuing evolocumab, the prescriber should be aware that the 2019 FDA gabapentin-opioid safety communication [10] is no longer relevant once opioids are discontinued, but the baseline sedation risk from the opioid period may take weeks to normalize.

Summary Decision Framework for the Prescribing Clinician

A practical approach to co-prescribing evolocumab and gabapentin involves three sequential checks.

Step 1: Confirm renal function. Obtain or verify current eGFR. Adjust gabapentin dose per the renal dosing table above before initiating therapy.

Step 2: Audit the full CNS medication burden. List all CNS-active agents: opioids, benzodiazepines, muscle relaxants, antihistamines, and other anticonvulsants. Gabapentin's sedation effect is additive with each of these. Evolocumab adds no CNS burden, but documenting the full picture prevents an attribution error if sedation emerges after evolocumab is added.

Step 3: Schedule LDL-C follow-up. Evolocumab should reduce LDL-C by 55 to 75% from baseline within 4 to 8 weeks [1]. If LDL-C reduction is inadequate, assess injection technique, cold-chain maintenance, and adherence before attributing the result to a drug interaction, because no pharmacokinetic interaction with gabapentin is expected.